Bank of New York Mellon Corp raised its position in Endocyte, Inc. (NASDAQ:ECYT) by 13.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 276,411 shares of the biopharmaceutical company’s stock after purchasing an additional 33,362 shares during the quarter. Bank of New York Mellon Corp owned 0.39% of Endocyte worth $4,910,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Endocyte in the 3rd quarter worth about $117,000. WINTON GROUP Ltd purchased a new stake in Endocyte in the 3rd quarter worth about $222,000. United Services Automobile Association purchased a new stake in Endocyte in the 2nd quarter worth about $181,000. Birchview Capital LP raised its position in Endocyte by 40.0% in the 3rd quarter. Birchview Capital LP now owns 14,000 shares of the biopharmaceutical company’s stock worth $249,000 after purchasing an additional 4,000 shares during the period. Finally, ING Groep NV purchased a new stake in Endocyte in the 3rd quarter worth about $404,000. 75.62% of the stock is currently owned by institutional investors.

Shares of ECYT stock opened at $23.99 on Thursday. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -23.99 and a beta of -0.01. Endocyte, Inc. has a one year low of $2.81 and a one year high of $24.00.

A number of analysts recently weighed in on the stock. BidaskClub raised shares of Endocyte from a “hold” rating to a “buy” rating in a research report on Tuesday, December 11th. Wedbush lowered shares of Endocyte from an “outperform” rating to a “neutral” rating in a research report on Thursday, October 18th. Wells Fargo & Co lowered shares of Endocyte from an “outperform” rating to a “market perform” rating in a research report on Friday, October 19th. Finally, Zacks Investment Research lowered shares of Endocyte from a “buy” rating to a “hold” rating in a research report on Wednesday, November 28th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $20.00.

ILLEGAL ACTIVITY NOTICE: “Endocyte, Inc. (ECYT) Position Increased by Bank of New York Mellon Corp” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/endocyte-inc-ecyt-position-increased-by-bank-of-new-york-mellon-corp/2819239.html.

Endocyte Profile

Endocyte, Inc, a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

See Also: What is a Derivative?

Want to see what other hedge funds are holding ECYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endocyte, Inc. (NASDAQ:ECYT).

Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.